Although the SMYD2 inhibitor LLY-507 has been elucidated to repress the proliferation of esophageal, breast, and liver cancers, this compound is a potent inhibitor (<1 μM) of several enzymes (http://www.chemicalprobes.org) which could complicate the interpretation of the cell proliferation data [40]. This evidence concerns the gene SMYD2 and liver cancer.